Last reviewed · How we verify
Metoprolole (Selo-Zok ®)
Metoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of norepinephrine and epinephrine on the heart.
Metoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Angina pectoris, Myocardial infarction (secondary prevention).
At a glance
| Generic name | Metoprolole (Selo-Zok ®) |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Beta-1 selective adrenergic antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Metoprolol competitively blocks beta-1 adrenergic receptors on cardiac tissue, decreasing heart contractility and heart rate. This reduces cardiac oxygen demand and blood pressure, making it effective for hypertension and angina. It also has antiarrhythmic properties useful in atrial fibrillation management.
Approved indications
- Hypertension
- Angina pectoris
- Acute myocardial infarction
- Heart failure
- Atrial fibrillation
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Dyspnea
- Depression
- Sexual dysfunction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metoprolole (Selo-Zok ®) CI brief — competitive landscape report
- Metoprolole (Selo-Zok ®) updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI